#Japan #Tokyo #Ibezapolstat #Acurx Pharmaceuticals #DNA Polymerase

Acurx Pharmaceuticals Expands Patent Portfolio with New Approvals

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP), a biopharmaceutical company focused on developing novel antibiotics, has recently announced significant milestones in its intellectual property journey. Following the granting of new patents by the Japan Patent Office and the Mexico Patent Office for the company’s DNA Polymerase IIIC inhibitors, Acurx is well on its way to establishing a robust presence in the global market of antibiotic treatments.

Background of Acurx Pharmaceuticals

Founded with the mission to tackle hard-to-treat bacterial infections, Acurx has been at the forefront of innovation in antibiotic therapy. As part of their strategy, the company has developed a new class of small molecule antibiotics designed to address serious infections, which are becoming increasingly resistant to traditional treatments.

With the recent patent grants in Japan and Mexico, Acurx enhances its intellectual property protection not only in the U.S.—where it has already secured six patents—but also in other key markets worldwide. This signifies a remarkable achievement in protecting critical innovations associated with their leading antibiotic candidate, ibezapolstat, which specifically targets DNA Polymerase IIIC.

The Significance of the Patents

The newly acquired patents cover various aspects of Acurx's drug formulation, methods of use, and pharmaceutical compositions. This adds to a growing portfolio that currently comprises a total of ten international patents across countries, including Australia, Canada, Europe, Israel, India, and Korea. These protections are crucial for ensuring Acurx maintains its competitive edge within the biopharmaceutical landscape.

David P. Luci, President and CEO of Acurx, expressed his enthusiasm: "Achieving these additional new patents extends our patent estate protection as we further develop ibezapolstat and our innovative, AI-supported drug discovery platform." This statement reflects the company’s commitment to the advancement of its antibiotic candidates and continual improvement in their research and development efforts.

Acurx's Pipeline of Antibiotics

Acurx’s primary focus is on its lead product, ibezapolstat, which is aimed at treating Clostridioides difficile infection (CDI). With preparations for an upcoming Phase 3 trial, Acurx is gearing up to secure funding for its clinical trials. Recent consultations with the FDA have indicated a potential pathway for filing a New Drug Application, contingent upon successful outcomes from ongoing research. This includes both treatment and recurrence reduction of CDI, a significant infection that presents challenges in clinical settings.

Further, Acurx is advancing its pipeline to include an oral formulation designed to treat acute bacterial skin and skin structure infections (ABSSSI) while simultaneously planning for the development of treatment for inhalational anthrax. This dual approach with both systemic and oral antibiotics illustrates Acurx's commitment to addressing various life-threatening infections across a spectrum of healthcare needs.

Expert Perspectives

Robert J. DeLuccia, Executive Chairman of Acurx, underscores the transformative potential of ibezapolstat, saying, "We believe Acurx's ibezapolstat and preclinical pipeline... have the potential to create a transformational shift in the treatment paradigm of certain serious and potentially life-threatening infections without promoting antibiotic-induced gut dysbiosis." This emphasizes Acurx's focus not only on efficiency but also on the safety of their antibiotic treatments.

In conclusion, the recent patent grants for Acurx Pharmaceuticals illustrate a strategic advancement in their mission to develop innovative antibiotic therapies. With these protections in place, Acurx is poised to make meaningful contributions to the field of infectious disease management, addressing critical health challenges head-on and potentially changing treatment protocols for antibiotic-resistant infections. As the company prepares for the next steps in clinical trials, the healthcare community eagerly anticipates further developments from this promising biopharmaceutical leader.